Arrowhead $ARWR saw a 22% increase in sales of its drug plozasiran thanks to positive results from Phase 3 clinical trials.


The medicine reduced the risk of pancreatitis by 100% this achievement was described as a "best-case scenario" in the medical community.
ARWR21.35%
post-image
post-image
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pinned